AAPL325.90-0.70 (-0.21%) ▼|ABBV255.44+2.06 (+0.81%) ▲|ABT101.56-0.10 (-0.10%) ▼|ACN142.90-1.83 (-1.26%) ▼|ADBE229.06-5.68 (-2.42%) ▼|AMAT560.93+35.23 (+6.70%) ▲|AMD525.38+21.81 (+4.33%) ▲|AMGN367.54+3.37 (+0.93%) ▲|AMT164.90-2.16 (-1.29%) ▼|AMZN247.17-2.82 (-1.13%) ▼|AVGO382.16+4.00 (+1.06%) ▲|AXP351.93-3.42 (-0.96%) ▼|BA209.48-4.55 (-2.13%) ▼|BAC60.42-0.85 (-1.39%) ▼|BKNG179.45-2.23 (-1.23%) ▼|BLK1,054.11-18.09 (-1.69%) ▼|BMY60.16-0.58 (-0.95%) ▼|BNY156.93-0.20 (-0.13%) ▼|BRK-B491.25+0.34 (+0.07%) ▲|C128.72-0.64 (-0.49%) ▼|CAT864.30-14.35 (-1.63%) ▼|CL91.93-0.52 (-0.56%) ▼|CMCSA23.78-0.01 (-0.04%) ▼|COF206.77-1.26 (-0.61%) ▼|COP115.68+0.97 (+0.85%) ▲|COST935.80-5.07 (-0.54%) ▼|CRM173.79+3.02 (+1.77%) ▲|CSCO110.70-1.24 (-1.11%) ▼|CVS107.61+0.14 (+0.13%) ▲|CVX189.71+2.33 (+1.24%) ▲|DE586.00-11.24 (-1.88%) ▼|DHR201.11-2.72 (-1.33%) ▼|DIS96.41-1.26 (-1.29%) ▼|DUK125.85+0.84 (+0.67%) ▲|EMR136.58-2.96 (-2.12%) ▼|FDX306.22-6.76 (-2.16%) ▼|GD370.60+2.02 (+0.55%) ▲|GE341.30-7.53 (-2.16%) ▼|GEV1,079.18+21.34 (+2.02%) ▲|GILD133.21-1.07 (-0.80%) ▼|GM75.80-0.27 (-0.35%) ▼|GOOG351.37+5.25 (+1.52%) ▲|GOOGL351.99+5.22 (+1.51%) ▲|GS1,055.03-10.19 (-0.96%) ▼|HD333.04-5.83 (-1.72%) ▼|HON226.18+1.16 (+0.52%) ▲|IBM213.00+0.33 (+0.16%) ▲|INTC97.06+2.02 (+2.13%) ▲|INTU293.82+2.73 (+0.94%) ▲|ISRG353.17+7.75 (+2.24%) ▲|JNJ248.82-4.22 (-1.67%) ▼|JPM338.87-2.23 (-0.65%) ▼|KO82.12+0.56 (+0.69%) ▲|LIN512.05-1.17 (-0.23%) ▼|LLY1,146.90-32.21 (-2.73%) ▼|LMT509.54+0.77 (+0.15%) ▲|LOW204.71-4.02 (-1.93%) ▼|LRCX306.76-6.54 (-2.09%) ▼|MA547.44+3.84 (+0.71%) ▲|MCD267.64-0.07 (-0.03%) ▼|MDLZ60.27-0.73 (-1.20%) ▼|MDT83.29+0.09 (+0.11%) ▲|META645.85-0.16 (-0.02%) ▼|MMM159.11-0.73 (-0.46%) ▼|MO74.66+0.45 (+0.61%) ▲|MRK124.40-3.10 (-2.43%) ▼|MS210.94-4.56 (-2.12%) ▼|MSFT402.29+8.47 (+2.15%) ▲|MU865.46+16.51 (+1.94%) ▲|NEE88.00-0.80 (-0.90%) ▼|NFLX67.60-1.35 (-1.96%) ▼|NKE43.47-0.29 (-0.66%) ▼|NOW104.70+1.46 (+1.41%) ▲|NVDA203.28+0.47 (+0.23%) ▲|ORCL121.38-5.03 (-3.98%) ▼|PEP135.46-1.66 (-1.21%) ▼|PFE24.75-0.30 (-1.20%) ▼|PG149.13-0.85 (-0.57%) ▼|PLTR134.85+2.47 (+1.87%) ▲|PM192.72-0.26 (-0.13%) ▼|QCOM170.32-1.46 (-0.85%) ▼|RTX194.44+0.93 (+0.48%) ▲|SBUX104.81-0.68 (-0.64%) ▼|SCHW102.54+0.98 (+0.96%) ▲|SO94.46-0.84 (-0.88%) ▼|SPG228.19-0.51 (-0.22%) ▼|T21.95+0.14 (+0.64%) ▲|TMO526.23-6.25 (-1.17%) ▼|TMUS195.64+3.21 (+1.67%) ▲|TSLA369.57-11.27 (-2.96%) ▼|TXN284.07+0.05 (+0.02%) ▲|UBER72.17-0.29 (-0.40%) ▼|UNH421.55-4.54 (-1.07%) ▼|UNP296.25-5.50 (-1.82%) ▼|UPS113.15-4.57 (-3.88%) ▼|USB63.14+0.00 (+0.00%) ▲|V360.57+2.01 (+0.56%) ▲|VZ43.50-0.09 (-0.21%) ▼|WFC86.33-1.18 (-1.35%) ▼|WMT112.20-2.04 (-1.79%) ▼|XOM148.36+1.00 (+0.68%) ▲|AAPL325.90-0.70 (-0.21%) ▼|ABBV255.44+2.06 (+0.81%) ▲|ABT101.56-0.10 (-0.10%) ▼|ACN142.90-1.83 (-1.26%) ▼|ADBE229.06-5.68 (-2.42%) ▼|AMAT560.93+35.23 (+6.70%) ▲|AMD525.38+21.81 (+4.33%) ▲|AMGN367.54+3.37 (+0.93%) ▲|AMT164.90-2.16 (-1.29%) ▼|AMZN247.17-2.82 (-1.13%) ▼|AVGO382.16+4.00 (+1.06%) ▲|AXP351.93-3.42 (-0.96%) ▼|BA209.48-4.55 (-2.13%) ▼|BAC60.42-0.85 (-1.39%) ▼|BKNG179.45-2.23 (-1.23%) ▼|BLK1,054.11-18.09 (-1.69%) ▼|BMY60.16-0.58 (-0.95%) ▼|BNY156.93-0.20 (-0.13%) ▼|BRK-B491.25+0.34 (+0.07%) ▲|C128.72-0.64 (-0.49%) ▼|CAT864.30-14.35 (-1.63%) ▼|CL91.93-0.52 (-0.56%) ▼|CMCSA23.78-0.01 (-0.04%) ▼|COF206.77-1.26 (-0.61%) ▼|COP115.68+0.97 (+0.85%) ▲|COST935.80-5.07 (-0.54%) ▼|CRM173.79+3.02 (+1.77%) ▲|CSCO110.70-1.24 (-1.11%) ▼|CVS107.61+0.14 (+0.13%) ▲|CVX189.71+2.33 (+1.24%) ▲|DE586.00-11.24 (-1.88%) ▼|DHR201.11-2.72 (-1.33%) ▼|DIS96.41-1.26 (-1.29%) ▼|DUK125.85+0.84 (+0.67%) ▲|EMR136.58-2.96 (-2.12%) ▼|FDX306.22-6.76 (-2.16%) ▼|GD370.60+2.02 (+0.55%) ▲|GE341.30-7.53 (-2.16%) ▼|GEV1,079.18+21.34 (+2.02%) ▲|GILD133.21-1.07 (-0.80%) ▼|GM75.80-0.27 (-0.35%) ▼|GOOG351.37+5.25 (+1.52%) ▲|GOOGL351.99+5.22 (+1.51%) ▲|GS1,055.03-10.19 (-0.96%) ▼|HD333.04-5.83 (-1.72%) ▼|HON226.18+1.16 (+0.52%) ▲|IBM213.00+0.33 (+0.16%) ▲|INTC97.06+2.02 (+2.13%) ▲|INTU293.82+2.73 (+0.94%) ▲|ISRG353.17+7.75 (+2.24%) ▲|JNJ248.82-4.22 (-1.67%) ▼|JPM338.87-2.23 (-0.65%) ▼|KO82.12+0.56 (+0.69%) ▲|LIN512.05-1.17 (-0.23%) ▼|LLY1,146.90-32.21 (-2.73%) ▼|LMT509.54+0.77 (+0.15%) ▲|LOW204.71-4.02 (-1.93%) ▼|LRCX306.76-6.54 (-2.09%) ▼|MA547.44+3.84 (+0.71%) ▲|MCD267.64-0.07 (-0.03%) ▼|MDLZ60.27-0.73 (-1.20%) ▼|MDT83.29+0.09 (+0.11%) ▲|META645.85-0.16 (-0.02%) ▼|MMM159.11-0.73 (-0.46%) ▼|MO74.66+0.45 (+0.61%) ▲|MRK124.40-3.10 (-2.43%) ▼|MS210.94-4.56 (-2.12%) ▼|MSFT402.29+8.47 (+2.15%) ▲|MU865.46+16.51 (+1.94%) ▲|NEE88.00-0.80 (-0.90%) ▼|NFLX67.60-1.35 (-1.96%) ▼|NKE43.47-0.29 (-0.66%) ▼|NOW104.70+1.46 (+1.41%) ▲|NVDA203.28+0.47 (+0.23%) ▲|ORCL121.38-5.03 (-3.98%) ▼|PEP135.46-1.66 (-1.21%) ▼|PFE24.75-0.30 (-1.20%) ▼|PG149.13-0.85 (-0.57%) ▼|PLTR134.85+2.47 (+1.87%) ▲|PM192.72-0.26 (-0.13%) ▼|QCOM170.32-1.46 (-0.85%) ▼|RTX194.44+0.93 (+0.48%) ▲|SBUX104.81-0.68 (-0.64%) ▼|SCHW102.54+0.98 (+0.96%) ▲|SO94.46-0.84 (-0.88%) ▼|SPG228.19-0.51 (-0.22%) ▼|T21.95+0.14 (+0.64%) ▲|TMO526.23-6.25 (-1.17%) ▼|TMUS195.64+3.21 (+1.67%) ▲|TSLA369.57-11.27 (-2.96%) ▼|TXN284.07+0.05 (+0.02%) ▲|UBER72.17-0.29 (-0.40%) ▼|UNH421.55-4.54 (-1.07%) ▼|UNP296.25-5.50 (-1.82%) ▼|UPS113.15-4.57 (-3.88%) ▼|USB63.14+0.00 (+0.00%) ▲|V360.57+2.01 (+0.56%) ▲|VZ43.50-0.09 (-0.21%) ▼|WFC86.33-1.18 (-1.35%) ▼|WMT112.20-2.04 (-1.79%) ▼|XOM148.36+1.00 (+0.68%) ▲|
23.6 C
New York
Tuesday, July 21, 2026

Tag: clinical benefit

newssourceFORcompanyinformationcontent1releasesmarket

Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Test

Approval expands access to Castle's precision medicine test designed to guide systemic treatment decision making in patients with moderate-to-severe atopic dermatitisFRIENDSWOOD, Texas, July 14,...

Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of...

WILMETTE, Ill., June 26, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that new analyses from the Phase 3 FoCus randomized controlled clinical trial of ALXN1840 (tiomolibdate choline, TMC) will be presented at the 12th Congress of the European Academy of Neurology (EAN 2026), June 27–30, 2026, in Geneva, Switzerland. These analyses build upon the previously reported Phase 3 FoCus results demonstrating ALXN1840 met its primary endpoint of superior copper mobilization versus standard of care.

NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer’s Disease

PrimeC was associated with changes across multiple biomarkers spanning key neurodegenerative disease pathways, providing early biological evidence consistent with potential target engagementFindings support continued...

AI-Powered Analysis by HistoIndex Reveals Robust Liver Fibrosis Improvement with D&D Pharmatech’s Zabopegdutide in Phase 2 MASH Trial

SINGAPORE and SEOUL, South Korea, June 18, 2026 /PRNewswire/ -- HistoIndex, a leader in AI-powered digital pathology solutions for fibrosis assessment, and D&D Pharmatech,...

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026

VANCOUVER, British Columbia, June 14, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today presented new clinical data from the dose-escalation portion of its ongoing Phase 1 study evaluating ZW191, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), at the European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress 2026.

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2...

– Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp score (NPS) in approximately 80% of participants –

Lilly’s Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with...

BRUIN CLL-322 is the first Phase 3 study to demonstrate superiority over a venetoclax-containing control arm in CLL, and, with the majority of patients...

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

TALVEY® plus DARZALEX FASPRO® with or without pomalidomide showed progression-free survival of up to 81% and overall survival of up to 89% at 24 monthsMonumenTAL-3 is the...

Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes

FDA approves Sanofi's Tzield as first disease-modifying therapy for children 8-17 with stage 3 type 1 diabetes, delaying insulin decline based on PROTECT

IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants

SOUTH SAN FRANCISCO, Calif., June 8, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the pricing of an underwritten public offering of common...

Everest Medicines Enters into Exclusive Asia-Pacific Licensing Agreement with Vcare PharmaTech for Sumecigrel

SHANGHAI, June 9, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing,...

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978 

JJP Biologics Announces Positive Interim Phase 1b Data for Nebaprubart (JJP-1212), an Anti-CD89 Antagonist, in Linear IgA Disease (LAD)

Warsaw, Poland – June 03, 2026 – JJP Biologics, ("JJPBio" or the "Company") a clinical-stage, immune-focused biotech that engineers precision antibodies to correct derailed immune pathways that drive autoimmune diseases and cancer, today announces positive interim data from its ongoing Phase 1b trial evaluating nebaprubart, also known as JJP-1212, its investigational potential first-in-class anti-CD89 antagonist, in patients diagnosed with Linear IgA Disease (LAD), a rare autoantibody-mediated skin disease.

/C O R R E C T I O N — Ranok Therapeutics/

In the news release, Ranok Therapeutics Announces Positive Interim Phase 1 Data Of Its KRAS G12D Inhibitor RNK08954 In Patients With KRAS G12D-Mutated Metastatic...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsClinical benefit

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers